Published in final edited form as:

Transl Neurosci. 2010 June 1; 1(2): 95–100. doi:10.2478/v10134-010-0022-y.

POTENTIAL APPLICATION OF GRAPE DERIVED POLYPHENOLS IN HUNTINGTON'S DISEASE

Jun Wang^{1,2}, Cathie M. Pfleger³, Lauren Friedman¹, Roselle Vittorino¹, Wei Zhao^{1,2},
Xianjuan Qian^{1,2}, Lindsay Conley¹, Lap Ho^{1,2,5}, and Giulio M. Pasinetti^{1,2,4,5,*}

¹Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029

²Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029

³Department of Oncological Science, Mount Sinai School of Medicine, New York, New York 10029

⁴Department of Neuroscience, Mount Sinai School of Medicine, New York, New York 10029

⁵Geriatric Research Education and Clinical Center, James J. Peters Veterans Affairs Medical Center, Bronx, New York 10468

Abstract

Huntington's disease (HD) is a progressive neurodegenerative disorder associated with selective neuronal cell death. Abnormal aggregation of huntingtin protein with polyQ expansion has been shown to be causally linked to HD. Grape seed polyphenolic extract (GSPE) is a natural compound that has previously been shown to interfere with aggregations of proteins involved in neurological disorders, such as amyloid beta peptides (A β) and Tau protein. In this study we found that GSPE treatment significantly inhibits polyQ aggregation in phaeochromocytoma (PC)-12 cell line containing an ecdysone-inducible protein comprising the first 17 amino acid of huntingtin plus 103 glutamines fused with enhanced GFP. In vivo feasibility studies using the *Q93htt exon1* drosophila model of HD, we extended our in vitro evidence and found that flies fed with GSPE had a significantly improved lifespan compared to the control flies. Using the R6/2 rodent model of HD, we found that oral administration of 100 mg/kg/day GSPE (equivalent to 500mg per day in human) significantly attenuated the motor skill decay as well as extended the lifespan in the R6/2 mice relative to vehicle-control mice. Collectively, our studies strongly suggest that GSPE might be able to modulate the onset and/or progression of HD.

Keywords

Neurological disorders; Motor function; Abnormal protein aggregation; Huntingtin protein; Drosophila; PC-12 cell; R6/2 mouse

1. Introduction

Huntington's disease (HD) is an autosomal-dominant neurological disorder that is caused by an unstable trinucleotide CAG repeat expansion at the N-terminus of the IT-15 gene, encoding the ~350 kDa huntingtin protein (htt) [1]. The mutation leads to production of htt proteins with an abnormal length of polyglutamine (polyQ) repeats. It is hypothesized that the polyQ repeats causes a gain of function resulting in abnormal protein-protein interaction

* giulio.pasinetti@mssm.edu.

[2,3]. HD is estimated to affect five to seven people in 100,000 throughout the world [4]. Clinical manifestation of the disease is characterized by severe cognitive and personality changes [5–7], accompanied by coordination decline and motor deficits that eventually lead to immobility [8]. Currently, there is no cure for this devastating neurodegenerative disorder, and treatments are mainly focused on alleviating cognitive and psychological symptoms. Recent evidence indicates that mutant htt (mhtt) aggregation in susceptible brain cells may be responsible for the onset and progression of HD phenotypes, and that the pathology and death of affected neurons are associated with the accumulation of mutant proteins in insoluble aggregates [9–12]. There are still debates regarding the role of aggregation in disease pathogenesis and several studies showed that the formation of aggregation could be a protective/defensive mechanism [10,13,14]. However, therapeutic strategies targeting polyQ aggregation have demonstrated some efficacy in various models of HD [15–18], suggesting that inhibition of abnormal neuronal htt protein aggregation might be a novel approach for HD treatment.

We previously reported that treatment with a select grape seed polyphenolic extract (GSPE) significantly attenuates spatial memory impairment in a mouse model of AD phenotypes [19]. Using both physical and biochemical methodologies, we found that GSPE can directly interfere with abnormal aggregation of proteins involved in neurological disorders, such as A β peptides [19,20] and Tau proteins [21]. GSPE is also a strong antioxidant and powerful metal chelator that can effectively reduce reactive oxygen species in vivo. Previous studies have demonstrated increased oxidative damage in post-mortem brains of HD patients [22,23], and increased free radical production in animal models of HD [24], indicating the involvement of oxidative stress in HD pathogenesis. Based on these findings, in the present study we explore the role of GSPE in HD-type conditions. We report for the first time that GSPE treatment could significantly extend lifespan in the *UAS-Q93htt^{exon1}* drosophila model of HD, and attenuate HD phenotypes in the R6/2 mouse model of HD. Mechanisms through which GSPE may attenuate HD phenotypes include GSPE's strong antioxidant activity and demonstrated ability to attenuate abnormal aggregation of mhtt proteins.

2. Experiment Procedures

2.1 GSPE

In this study, MegaNatural grape seed polyphenolic extract (GSPE) was provided by Polyphenolics, Inc. (Madera, CA). It is a highly purified water-soluble polyphenolic preparation from *Vitis vinifera* seeds [25] which does not contain detectable resveratrol. Typically, MegaNatural GSPE contains approximately 8% monomers, 75% oligomers and 17% polymers. We arbitrarily used the molecular weight of catechin and epicatechin dimer (which is the most abundant form of oligomers in GSPE) to calculate the molarity for GSPE in this study.

2.2 Drosophila strains and GSPE treatment

Expression of polyQ-containing peptides is driven by the bipartite expression system upstream activator sequence (UAS)-GAL4 in transgenic flies [26]. w; *UAS-Q93htt^{exon1}* flies were obtained from Dr. Ivana Delalle. *elav-GAL4* flies (Flybase ID FBti0072910) were obtained from the Bloomington Stock Center. *Elav-GAL4* flies were crossed to *UAS-Q93htt^{exon1}* flies to generate *elav>Q93htt^{exon1}* flies. Lifespans were generated by collecting newly enclosed animals, placing them at low density 10 animals per vial, either on control food (fly medium formula 4–24) or GSPE food (fly medium formula 4–24 supplemented with 2.8 μ g/ml GSPE). The animals were counted each day and transferred to fresh vials every few days. Lifespans were generated by calculating the percentage of survivors daily and plotting this as a function of time in days.

2.3 R6/2 mice and GSPE treatment

R6/2 ovarian transplant female mice [27] were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). R6/2 ovarian transplanted female mice were randomly divided into two groups (the 100 mg/kg/day GSPE treatment group and the H₂O treated control group), and mated with wild type male mice. The weaning pups were continuously fed on the same treatment regimen as their parents. The resulting R6/2 mice and age-, strain-, and gender-matched wild type littermates were both included in the study. All procedures and protocols were approved by the Mount Sinai School of Medicine's Institutional Animal Care and Use Committee (IACUC) through the Center for Comparative Medicine and Surgery.

2.4 Rotarod behavior test

We used rotarod to assess motor functions in the mice. HD transgenic mice were trained to stay on a narrow rod in an accelerating rotarod apparatus (4 rpm- 40 rpm in 10 minutes) at 6 weeks of age, and rotarod performance was monitored once a week starting at 8 weeks of age. Three trials were conducted for each test given, and the average of the three trials was recorded. Loss of motor function is reflected by reduced latency time before the animals fall off the apparatus.

2.5 Rat adrenal pheochromocytoma PC-12 cells

PC-12 cells stably transfected with an ecdysone-inducible protein comprising the first 17 amino acids of huntingtin plus 103 glutamines fused with enhanced GFP [17] were used for the in vitro cell based study. Cells were grown in humidified 5% CO₂ incubators at 37°C. The medium comprises DMEM supplemented with 10% FBS, 1 mg/ml geneticin, zeocin and penicillin-streptomycin (all drugs are from Invitrogen). At 50% cell confluence level, 0.2 μ M of muristerone A (Invitrogen) was used to induce the expression of the transgene.

2.6 Western blot analysis

48 hours after muristerone A induction, cells were washed once with cold phosphate buffered saline (PBS, pH 7.4) and harvested with lysis buffer and boiled. 25 μ g protein was loaded on the 4–16% Bis-Tris gel and transferred on the nitrocellulose membrane. The western procedure was performed as previously described [28]. The antibodies used were: mouse monoclonal anti-polyQ-expansion antibody (Millipore); rabbit anti-GFP antibody (Calbiochem); rabbit anti-actin antibody, HRP-conjugated anti-mouse antibody and HRP-conjugated anti-rabbit antibody (Santa Cruz Biotechnology).

2.7 Oxidation assay and antioxidant capacity assay

PC-12 *htt103Q-EGFP* cells were lysed with sucrose isolation buffer (0.32 M sucrose, 0.125 M Tris pH 8.0, 0.1 mM EDTA, and 0.6 mM MgCl₂ with protease inhibitors) supplemented with 50 mM DTT and the supernatants were collected. Carbonylated protein level was determined using commercially available OxyBlot protein oxidation detection kit (Chemicon International, MA) according to the manufacturer's instructions. Lipid oxidation and protein nitration were determined by western blot analysis using the protocol described by Owen *et al.* [29]. Antioxidant capacity was analyzed using a commercially available antioxidant assay kit (Cayman's Chemical, MI) according to manufacturer's instruction.

3. Statistical Analyses

2-tailed student t-tests were used for analyzing rotarod tests. For surviving studies in drosophila subjects, the results of the four mortality analyses on drosophila survival were compared by a chi-square test for the differences among the respective z statistics that were

obtained as square roots of the respective chi-squares on 1 degree of freedom from the Kaplan-Maier analyses. For surviving studies in mice, the log-rank test was used.

4. Results

4.1 GSPE treatment extends lifespan in the *elav>httQ3* fly model of HD

In this study, *elav-GAL4* flies were crossed with *UAS-Q93httexon1* male flies to generate *elav>Q93httexon1* flies. Lifespan experiments were only performed in male flies, since mating can affect female lifespan. Lifespan studies in the male *elav>Q93httexon1* flies revealed that GSPE significantly increased lifespan (Figure 1, $X^2 = 21.73$, $df = 1$, $p = 0.0001$). In control lifespan studies using wild type flies, we found that GSPE had no effect (data not shown). Four independent lifespan trials and a total of 114 flies per group were used in this test.

4.2 GSPE treatment improves motor function and extends lifespan in the R6/2 mouse model of HD

The R6/2 mouse model of HD generated by Dr. Bates and colleagues [27] was used for in vivo feasibility studies. Animals were treated with 100 mg/kg/day GSPE and motor coordination tests (by accelerating rotarod) showed no significant behavior difference between the treatment and control groups at 6 weeks of age, when these animals are mostly asymptomatic. However, at 9 and 11 weeks of age, at which time HD phenotypes have developed in this mouse model, the GSPE treated group performed significantly better on motor coordination test than the control mice (Figure 2A). In control studies in wild type mice, we found that GSPE treatment had no effect on motor function (data not shown).

In addition, we found that GSPE treatment significantly extended lifespan in R6/2 mice compared with water-treated control mice (Figure 2B, Log-rank test, $p = 0.0220$). The median lifespan for non-treated control R6/2 mice was 90.5 days, while GSPE treated mice had a median lifespan of 98 days.

4.3 GSPE treatment reduces protein aggregation in PC-12 htt103Q-EGFP cells

Given the anti-protein aggregation role of GSPE in other neurological disorders [19–21], and our finding that GSPE could significant reduce motor deficits and increase lifespan in two independent in vivo HD models, we next tested whether GSPE exerts its beneficial effect by interfering with the formation of polyQ-containing aggregates. Using the PC-12 cell line that contains an ecdysone-inducible protein comprised of the first 17 amino acids of huntingtin protein, plus 103 glutamines fused with enhanced GFP (Htt103Q-EGFP) [17], we found that, consistent with previous reports, induction of polyQ protein expression with 0.2 μ M muristerone A did not significantly affect cell viability. Induction of polyQ protein expression resulted in a range of polyQ antibody reactive species by western blot analysis, with molecular weight ranging from 55 kDa to 250 kDa. There was a visible smear of very high molecular weight polyQ reactive species in control cells, while treatment with 12.5 or 25 μ M GSPE significantly reduced the accumulation of high molecular weight htt aggregates in a concentration-dependent manner by western blot analysis, and treatment with 25 μ M GSPE completely diminished high molecular weight species (Figure 3A). This reduction in aggregates was also evident by reduced GFP aggregates under fluorescent microscope (Figure 3B). We also noted the smear between 36 kDa and 55 kDa in control cells which are much less in the 12.5 μ M GSPE treated cells and almost absent in the 25 μ M GSPE treated cells, which might be reflecting the degradation product of the high molecular weight species.

4.4 GSPE treatment reduces protein oxidation in PC-12 htt103Q-EGFP cells

Increased oxidative damage has been reported in HD brains for both human cases and experimental models of HD. Given that GSPE is a strong antioxidant, we tested whether treatment with GSPE might reduce oxidative stress in PC-12 cells expressing the mhtt protein. We first measured the antioxidant capacity of PC-12 cells upon GSPE treatment. The antioxidant capacity of the cells 48 hours after mhtt protein induction was 9.6 ± 0.3 mM/mg protein, while 12.5 μ M GSPE-treated cells with mtt protein induction had increased levels of antioxidant capacity (12.8 ± 1.9 mM/mg protein, $p < 0.05$). As protein carbonylation and nitration and lipid peroxidation are standard markers for oxidative stress, we next measured levels of protein carbonylation, 3-nitrotyrosine (3NT) for protein nitration, and protein-bound 4-hydroxynonenal (HNE) for lipid oxidation upon GSPE treatment. We found that levels of protein carbonyls were significantly elevated 48 hours after mhtt protein induction, compared to non-induced control cells (Figure 4, lane 3 vs lane 1), confirming that polyglutamine aggregates could potentially induce oxidative stress. Further, treatment with 12.5 μ M GSPE significantly reduced the level of carbonyls (Figure 4, lane 4 vs lane 3), consistent with the antioxidant capacity analysis. Treatment with GSPE significantly reduced the amount of aggregated proteins in PC-12 cells, which could have in turn reduced the level of oxidative stress (although it is plausible that GSPE could be directly involved in oxidative stress reduction). No significant alteration was found in the levels of 3NT or protein-bound 4-HNE (data not shown) in GSPE-treated cells.

5. Discussion

HD is a devastating neurological disease caused by abnormal trinucleotide CAG repeats. It is associated with neuronal intranuclear inclusions (NIIs) as well as cytoplasmic inclusions containing truncated polyQ fragments [2,30], resulting in progressive neuronal loss in the caudate and putamen [31]. Currently there is no cure.

Overexpressing disease-associated aggregation-prone proteins has been used previously to model aspects of HD in *Drosophila* [32–35]. Expression of Gal4 in a pan-neural pattern (*elav-Gal4*) in transgenic lines containing *UAS-Q93htt exon1* results in adult-onset neurodegeneration, including the disruption of photoreceptor cells of the eye, impairments of climbing ability, and reduced lifespan. In this study, we demonstrated that GSPE could effectively improve survival in the *Drosophila* models of HD. To further assess the *in vivo* efficacy of GSPE, we also used a well-established mouse model of HD, specifically the R6/2 mice which exhibit a very aggressive neurological phenotype and provide clear experimental endpoints, which are ideal for preclinical feasibility study [27,36]. Treatment of R6/2 mice with 100 mg/kg/day GSPE significantly alleviated the deterioration of motor function and extended lifespan.

We have previously shown that GSPE could physically interfere with A β and Tau peptide aggregation [19–21]. Others have demonstrated that green tea polyphenol epigallocatechin-gallate was able to inhibit htt exon 1 aggregation and reduce motor impairment in HD flies [18]. Using PC-12 cells overexpressing *htt103Q-EGFP*, we demonstrated that GSPE could inhibit polyQ-htt aggregation in an *in vitro* tissue culture system. Moreover, GSPE could also increase antioxidant capacity and reduce the amount of carbonylated protein content in cells expressing mhtt aggregates, which is consistent with their strong antioxidant activity.

A unique feature of GSPE is that it is readily absorbed through the intestinal mucosa due to the modification of the constituent polyphenols [37]. Moreover, GSPE is well-tolerated in both humans and rodents [38]. One of the main obstacles for applying polyphenolic compound in the treatment of neurological disorders is the limited understanding of their bioactivity and whether they can pass the blood brain barrier and reach the central nervous

system. In a recent bioavailability studies, we showed that GSPE and its metabolites can be detected in the brain when delivered at doses in the equivalent range of that employed in our feasibility studies using the R6/2 mouse model of HD [39]. In summary, our study demonstrated that GSPE could inhibit polyQ-htt aggregation in PC-12 cells expressing mhtt protein and reduce the oxidative stress induced by the expression of mhtt protein. Most importantly, oral treatment in both drosophila and mouse models of HD with GSPE effectively reduced motor deficits and extended lifespan. Our studies demonstrated strong evidence of preclinical efficacy of GSPE in HD treatment, and provide impetus for the application of GSPE for human clinical testing.

Acknowledgments

This work was supported by Polyphenolics, Inc. We thank Hayley Fivecoat for assistance in the preparation of the manuscript.

References

1. MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. *Cell* 1993 Mar 26;72(6):971–983. [PubMed: 8458085]
2. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. *Cell* 1997 Aug 8;90(3):537–548. [PubMed: 9267033]
3. Trotter Y, Lutz Y, Stevanin G, Imbert G, Devys D, Cancel G, et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. *Nature* 1995 Nov 23;378(6555):403–406. [PubMed: 7477379]
4. Walker FO. Huntington's disease. *Lancet* 2007 Jan 20;369(9557):218–228. [PubMed: 17240289]
5. Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC. Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. *Biol Psychiatry* 2007 Dec 15;62(12):1341–1346. [PubMed: 17481592]
6. Johnson SA, Stout JC, Solomon AC, Langbehn DR, Aylward EH, Cruce CB, et al. Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. *Brain* 2007 Jul;130(Pt 7):1732–1744. [PubMed: 17584778]
7. Solomon AC, Stout JC, Johnson SA, Langbehn DR, Aylward EH, Brandt J, et al. Verbal episodic memory declines prior to diagnosis in Huntington's disease. *Neuropsychologia* 2007 Apr 9;45(8):1767–1776. [PubMed: 17303196]
8. Penney JB Jr, Young AB, Shoulson I, Starosta-Rubenstein S, Snodgrass SR, Sanchez-Ramos J, et al. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. *Mov Disord* 1990;5(2):93–99. [PubMed: 2139171]
9. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. *Cell* 1997 Aug 8;90(3):537–548. [PubMed: 9267033]
10. Bates, Gillian; Harper, Peter S.; Jones, Lesley. *Huntington's Disease Third Edition*. Oxford University Press; 2002.
11. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. *Cell* 2000;101(1):57–66. [PubMed: 10778856]
12. Yang W, Dunlap JR, Andrews RB, Wetzel R. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. *Hum Mol Genet* 2002 Nov 1;11(23):2905–2917. [PubMed: 12393802]
13. Watase K, Weeber EJ, Xu B, Antalffy B, Yuva-Paylor L, Hashimoto K, et al. A long CAG repeat in the mouse Scn1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. *Neuron* 2002 Jun 13;34(6):905–919. [PubMed: 12086639]

14. Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. *Cell* 1998 Oct 2;95(1):55–66. [PubMed: 9778247]
15. Sanchez I, Mahlke C, Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. *Nature* 2003 Jan 23;421(6921):373–379. [PubMed: 12540902]
16. Kazantsev A, Walker HA, Slepko N, Bear JE, Preisinger E, Steffan JS, et al. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in *Drosophila*. *Nat Genet* 2002 Apr;30(4):367–376. [PubMed: 11925563]
17. Apostol BL, Kazantsev A, Raffioni S, Illes K, Pallos J, Bodai L, et al. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in *Drosophila*. *Proceedings of the National Academy of Sciences of the United States of America* 2003 May 13;100(10):5950–5955. [PubMed: 12730384]
18. Ehrnhoefer DE, Duennwald M, Markovic P, Wacker JL, Engemann S, Roark M, et al. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. *Hum Mol Genet* 2006 Sep 15;15(18):2743–2751. [PubMed: 16893904]
19. Wang J, Ho L, Zhao W, Ono K, Rosensweig C, Chen L, et al. Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. *J Neurosci* 2008 Jun 18;28(25):6388–6392. [PubMed: 18562609]
20. Ono K, Condon MM, Ho L, Wang J, Zhao W, Pasinetti GM, et al. Effects of Grape Seed-derived Polyphenols on Amyloid {beta}-Protein Self-assembly and Cytotoxicity. *J Biol Chem* 2008 Nov 21;283(47):32176–32187. [PubMed: 18815129]
21. Ho L, Yemul S, Wang J, Pasinetti G. Grape seed polyphenolic extract (GSE) as a novel therapeutic reagent in tau-mediated neurodegenerative disorders. *J Alzheimers Dis.* 2009
22. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. *Ann Neurol* 1997 May;41(5):646–653. [PubMed: 9153527]
23. Browne SE, Ferrante RJ, Beal MF. Oxidative stress in Huntington's Oxidative stress in Huntington's. *Brain Pathol* 1999 Jan;9(1):147–163. [PubMed: 9989457]
24. Bogdanov MB, Andreassen OA, Dedeoglu A, Ferrante RJ, Beal MF. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. *J Neurochem* 2001 Dec;79(6):1246–1249. [PubMed: 11752065]
25. Wang J, Ho L, Zhao Z, Seror I, Humala N, Dickstein D, et al. Moderate consumption of Cabernet Sauvignon attenuates Ab neuropathology in a mouse model of Alzheimer's disease. *FASEB.* 2006 Jan 11; in press.
26. Marsh JL, Walker H, Theisen H, Zhu YZ, Fielder T, Purcell J, et al. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in *Drosophila*. *Hum Mol Genet* 2000 Jan 1;9(1):13–25. [PubMed: 10587574]
27. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. *Cell* 1996;87(3):493–506. [PubMed: 8898202]
28. Wang J, Ho L, Qin W, Rocher AB, Seror I, Humala N, et al. Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. *FASEB J* 2005 Apr;19(6):659–661. [PubMed: 15650008]
29. Owen JB, Opii WO, Ramassamy C, Pierce WM, Butterfield DA. Proteomic analysis of brain protein expression levels in NF-[kappa] [beta] p50 -/- homozygous knockout mice. *Brain Research* 2008 Nov 13;1240:22–30. [PubMed: 18817763]
30. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. *Science* 1997;277(5334):1990–1993. [PubMed: 9302293]
31. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. *J Neuropathol Exp Neurol* 1985 Nov;44(6):559–577. [PubMed: 2932539]

32. Warrick JM, Paulson HL, Gray-Board, Bui QT, Fischbeck KH, Pittman RN, et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in *Drosophila*. *Cell* 1998 Jun 12;93(6):939–949. [PubMed: 9635424]
33. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in *Drosophila*. *Nature* 2001 Oct 18;413(6857):739–743. [PubMed: 11607033]
34. Wolfgang WJ, Miller TW, Webster JM, Huston JS, Thompson LM, Marsh JL, et al. Suppression of Huntington's disease pathology in *Drosophila* by human singlechain Fv antibodies. *Proc Natl Acad Sci U S A* 2005 Aug 9;102(32):11563–11568. [PubMed: 16061794]
35. Agrawal N, Pallos J, Slepko N, Apostol BL, Bodai L, Chang LW, et al. Identification of combinatorial drug regimens for treatment of Huntington's disease using *Drosophila*. *Proc Natl Acad Sci U S A* 2005 Mar 8;102(10):3777–3781. [PubMed: 15716359]
36. Ramaswamy S, McBride J, Kordower J. Animal models of Huntington's disease. *ILAR J* 2007;48(4):356–373. [PubMed: 17712222]
37. Siva B, Edirisinghe I, Randolph J, Steinberg F, Kappagoda T. Effect of a polyphenolic extracts of grape seeds on blood pressure in patients with the metabolic syndrome. *The FASEB Journal* 20, A305-C. 2006
38. Bentivegna SS, Whitney KM. Subchronic 3-month oral toxicity study of grape seed and grape skin extracts. *Food and Chemical Toxicology* 2002 Dec;40(12):1731–1743. [PubMed: 12419686]
39. Ferruzzi MG, Lobo JK, Janle EM, Whittaker N, Cooper B, Simon JE, et al. Bioavailability of Gallic Acid and Catechins from Grape Seed Polyphenol Extract is Improved by Repeated Dosing in Rats: Implications for Treatment in Alzheimer's Disease. *J Alzheimers Dis.* 2009 Jul 20;

Figure 1.

GSPE extends lifespan in male HD flie. *elav> Q93htt exon1* male flies derived from crossing *elav-GAL4* and *UAS-Q93htt exon1* flies were collected within one day of eclosion and placed 10 per vial on control food (n=30) or GSPE food (n=30). Lifespan was generated by calculating the percentage of surviving flies daily. Four independent lifespan trials were conducted in this manner.

Figure 2.

The impact of GSPE on the motor function and survival in R6/2 mice (A) Motor functions of R6/2 mice were assessed using accelerating rotarod at 6 weeks, 9 weeks and 11 weeks. The average of three trials conducted for each test was recorded. Duration on the rotarod is defined as latency time taken the animals to fall off the apparatus. (B) R6/2 transgenic mice were treated either with 100 mg/kg/day GSPE or H₂O (as control group) and the survival rate was recorded daily.

Figure 3.

GSPE reduces Htt103Q-EGFP aggregation in PC-12 cell- based assay (A) Western blot analysis of PC12 cells expressing Htt103Q-EGFP in the absence (control) and presence of 12.5 μM and 25 μM 48 hours after 0.2 μM muristerone A induction. Left panel: western blot probed with anti-GFP antibody; right panel: densitometrical analysis of the western blot. (B) Representative fluorescent microscopy images of vehicle-treated control cells and cells treated with 12.5 μM and 25 μM GSPE after muristerone A induction; scale bar: 50 μm.

Figure 4.

GSPE reduces protein oxidation in PC-12 htt103Q-EGFP cells (A) Western blot assessment of carbonylated protein level in PC-12 cells in the presence or absence of 12.5 μ M GSPE with or without muristerone A induction. (B) Densitometrical analysis of the western blot. (C) Quantitative measure of carbonylated protein content as percentage of control (average of 3 independent experiments)